Understanding how AIRE and certain immune cells affect tumor growth and immune response
Elucidating the Role of AIRE and Tumor Associated Aire-expressing Cells in Tumor Growth and Immune Evasion
['FUNDING_FELLOWSHIP'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-11087455
This study is looking at how a gene called AIRE and certain immune cells work together in tumors, to understand how cancer can hide from our immune system, with the hope of finding new ways to help the body fight cancer better.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-11087455 on ClinicalTrials.gov |
What this research studies
This research investigates the role of the Autoimmune Regulator gene (AIRE) and specific immune cells in the tumor microenvironment, focusing on how they influence tumor growth and the body's immune response to cancer. By studying these interactions, the research aims to uncover mechanisms that allow tumors to evade the immune system. The approach involves using advanced techniques to analyze immune cell populations in various tumor models, with the goal of identifying potential therapeutic targets to enhance anti-tumor immunity.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with solid tumors who may benefit from enhanced immune responses against their cancer.
Not a fit: Patients with non-solid tumors or those who do not have an active immune response may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for improving cancer immunotherapy by targeting specific immune cells that inhibit anti-tumor responses.
How similar studies have performed: Previous research has shown promising results in targeting immune cells in the tumor microenvironment, suggesting that this approach could lead to significant advancements in cancer treatment.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ARVEDSON, MATTHEW — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- Study coordinator: ARVEDSON, MATTHEW
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anti-cancer therapy, anticancer immunotherapy, Autoimmune Diseases, autoimmune disorder